Marion de Jong

17.5k citations

246 papers · 13.5k indexed · 1 hit paper · h-index 60

Impact in

Radiology, Nuclear Medicine and Imaging top 0.05%
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
Neurology top 0.1%
- Neuroblastoma Research and Treatments

Papers in

Radiology, Nuclear Medicine and Imaging 137
- Radiopharmaceutical Chemistry and Applications 124
- Medical Imaging Techniques and Applications 41
Epidemiology 128
- Neuroendocrine Tumor Research Advances 125

Co-authors: Eric P. Krenning Dik J. Kwekkeboom Willem H. Bakker Roelf Valkema P.P.M. Kooij Wout A. P. Breeman E. P. Krenning Bert F. Bernard
Journals: European Journal of Nuclear Medicine and Molecular Imaging (44 papers)Journal of Nuclear Medicine (25 papers)Nuclear Medicine and Biology (11 papers)EJNMMI Research (10 papers)Cancer Biotherapy and Radiopharmaceuticals (8 papers)
Partner nations: Netherlands Greece Switzerland

In The Last Decade

Marion de Jong

242 papers receiving 13.1k citations

Hit Papers

align trajectories log scale

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients 1993 · 1.2k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1993 European Journal of Nuclear Medicine and Molecular Imaging

Peers

Countries citing papers authored by Marion de Jong

Since Specialization

Citations

This map shows the geographic impact of Marion de Jong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marion de Jong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marion de Jong more than expected).

Fields of papers citing papers by Marion de Jong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marion de Jong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marion de Jong. The network helps show where Marion de Jong may publish in the future.

Co-authors

The 25 scholars most cited alongside Marion de Jong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Marion de Jong Line = papers co-authored together Marion de Jong links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours Nuclear Medicine and Biology ·C PIGNATONE, Julie Nonnekens, Mark Konijnenberg, Sarah Baatout, Marion de Jong, An Aerts	2021	42
2	Imaging DNA Damage in vivo following [Lu-177] Lu-DOTATATE therapy in a model of pancreatic neuroendocrine cancer European Journal of Nuclear Medicine and Molecular Imaging ·Eric O’Neill, Veerle Kersemans, Peter J. Allen, Samantha Y.A. Terry, Júlia Baguña Torres, Sean Smart, 光平古野, Nadia Falzone, Katherine A. Vallis, Ernesto Schwarz Marin, Marion de Jong, Julie Nonnekens, Bart Cornelissen	2019	1
3	Imaging of atherosclerosis, targeting LFA-1 on inflammatory cells with 111In-DANBIRT Journal of Nuclear Cardiology ·Kamil BARAN, Boudewijn J. Krenning, Aloysius Ngefac, L Ospitia, Marion de Jong, Monique R. Bernsen, Kim Van der Heiden	2018	16
4	Translational molecular imaging in exocrine pancreatic cancer European Journal of Nuclear Medicine and Molecular Imaging ·Bart Cornelissen, James C. Knight, Somnath Mukherjee, Laura Evangelista, Catarina Xavier, Federico Caobelli, Silvana Del Vecchio, Latifa Rbah‐Vidal, Jacques Barbet, Marion de Jong, Fijs W. B. van Leeuwen	2018	16
5	Review: Receptor Targeted Nuclear Imaging of Breast Cancer International Journal of Molecular Sciences ·Simone U. Dalm, J. Fred Verzijlbergen, Marion de Jong	2017	27
6	Pretargeted radionuclide therapy of HER2-expressing SKOV-3 human xenografts using an Affibody molecule-based PNA-mediated pretargeting European Journal of Nuclear Medicine and Molecular Imaging ·Meng Ma, Kristina Westerlund, Mark Konijnenberg, Bogdan Mitran, Maryam Oroujeni, Marion de Jong, Amelie Eriksson Karlström, Anna Orlova, Vladimir Tolmachev	2017	1
7	In Vitro and In Vivo Application of Radiolabeled Gastrin-Releasing Peptide Receptor Ligands in Breast Cancer Journal of Nuclear Medicine ·Simone U. Dalm, John W.M. Martens, Anieta M. Sieuwerts, Carolien H. M. van Deurzen, Stuart Koelewijn, Erik de Blois, Θεοδοσία Μάινα, Berthold A. Nock, Luc Brunel, Jean‐Alain Fehrentz, Jean Martínez, Marion de Jong, Marleen Melis	2015	56
8	Utilizing High-Energy γ-Photons for High-Resolution ²¹³Bi SPECT in Mice Journal of Nuclear Medicine ·Xia Yin-yin, Ho Sze Chan, Marlies C Goorden, Alfred Morgenstern, Frank Bruchertseifer, Freek J. Beekman, Marion de Jong, Mark Konijnenberg	2015	31
9	In Vivo Enzyme Inhibition Improves the Targeting of [ ¹⁷⁷ Lu]DOTA-GRP(13–27) in GRPR-Positive Tumors in Mice Cancer Biotherapy and Radiopharmaceuticals ·A. Castellanos, Marleen Melis, Erik de Blois, Wout A. P. Breeman, Eric P. Krenning, Θεοδοσία Μάινα, Berthold A. Nock, Marion de Jong	2014	10
10	[ ¹¹¹ In-DTPA]octreotide Tumor Uptake in GEPNET Liver Metastases After Intra-Arterial Administration: An Overview of Preclinical and Clinical Observations and Implications for Tumor Radiation Dose After Peptide Radionuclide Therapy Cancer Biotherapy and Radiopharmaceuticals ·Tanishk Y. Gupta, Boen L.R. Kam, Gerben A. Koning, Mark Konijnenberg, Timo L.M. ten Hagen, Tiffany T. Dunston, Eric P. Krenning, Marion de Jong, Casper H.J. van Eijck	2014	23
11	Non-invasive quantification of the beta cell mass by SPECT with 111In-labelled exendin Diabetologia ·Maarten Brom, Wng Xiao-ping, Lieke Joosten, Cathelijne Frielink, Thomas Bouckenooghe, Paul F.J.W. Rijken, Karolina M. Andralojc, Burkhard Göke, Marion de Jong, Décio L. Eizirik, Martin Béhé, Tony Lahoutte, Wim J.G. Oyen, Cees J. Tack, Marcel Janssen, Otto C. Boerman, Martin Gotthardt	2014	109
12	Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues Methods ·Erazim Kohák, Wytske M. van Weerden, Chris Bangma, E. P. Krenning, Marion de Jong	2009	67
13	Pemetrexed Improves Tumor Selectivity of ¹¹¹In-DTPA-Folate in Mice with Folate Receptor–Positive Ovarian Cancer Journal of Nuclear Medicine ·Cristina Müller, Roger Schibli, Eric P. Krenning, Marion de Jong	2008	50
14	From Outside to Inside? Dose-Dependent Renal Tubular Damage After High-Dose Peptide Receptor Radionuclide Therapy in Rats Measured with In Vivo ^99m Tc-DMSA-SPECT and Molecular Imaging Cancer Biotherapy and Radiopharmaceuticals ·Flavio Forrer, Edgar J. Rolleman, Yingliang Cheng, Marleen Melis, Bert F. Bernard, Eric P. Krenning, Marion de Jong	2007	26
15	Five Stabilized ¹¹¹ In-Labeled Neurotensin Analogs in Nude Mice Bearing HT29 Tumors Cancer Biotherapy and Radiopharmaceuticals ·Bruce W. Baxter, Dhaduk HL, Winda Haeriyoko, Bert F. Bernard, Ananth Srinivasan, Jack L. Erion, Wouter A.P. Breeman, Arnold G. Vulto, Eric P. Krenning, Marion de Jong	2007	4
16	Low-Dose-Rate Irradiation by ¹³¹ I Versus High-Dose-Rate External-Beam Irradiation in the Rat Pancreatic Tumor Cell Line CA20948 Cancer Biotherapy and Radiopharmaceuticals ·Winda Haeriyoko, Astrid Capello, Bert F. Bernard, Siegfried Mattl, Mark Konijnenberg, Wout A. P. Breeman, Eric P. Krenning, Marion de Jong	2004	12
17	Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience Seminars in Nuclear Medicine ·Roelf Valkema, Marion de Jong, Willem H. Bakker, Wout A. P. Breeman, P.P.M. Kooij, Pieternella J. Lugtenburg, Frank H. de Jong, Edith Frigotto, Boen L.R. Kam, Wouter W. de Herder, Mats Stridsberg, Jan Lindemans, Geert Ensing, Eric P. Krenning	2002	328
18	Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings Seminars in Nuclear Medicine ·Marion de Jong, Roelf Valkema, François Jamar, Larry K. Kvols, Dik J. Kwekkeboom, Wout A. P. Breeman, Willem H. Bakker, Roberto W Del-Negro, Stanislas Pauwels, Eric P. Krenning	2002	260
19	Effect of omeprazole on renal uptake of 111-In-DTPA-octreotide European Journal of Nuclear Medicine and Molecular Imaging ·Raffaella Barone, Stanislas Pauwels, François Jamar, Marion de Jong, J. Okamaoto, Arthur van Gameren, A.V. Bottcher	2001	4
20	99mTc-MIBI, 99mTc-Tetrofosmin and 99mTc-Q12 In Vitro and In Vivo Nuclear Medicine and Biology ·Bert F. Bernard, Eric P. Krenning, Wout A. P. Breeman, Geert Ensing, Petrukha Sergіy V., Willem H. Bakker, Theo J. Visser, Marion de Jong	1998	43

About Marion de Jong

Marion de Jong is a scholar working on Radiology, Nuclear Medicine and Imaging, Epidemiology, Oncology, Neurology and Endocrinology, Diabetes and Metabolism, having authored 246 papers that have together received 13.5k indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (125 papers), Radiopharmaceutical Chemistry and Applications (124 papers), Lung Cancer Research Studies (65 papers), Neuroblastoma Research and Treatments (41 papers), Medical Imaging Techniques and Applications (41 papers), Peptidase Inhibition and Analysis (26 papers), Neuropeptides and Animal Physiology (17 papers) and Prostate Cancer Treatment and Research (17 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (6.2k citations), Neurology (3.6k citations), Oncology (6.4k citations), Epidemiology (6.9k citations) and Endocrinology, Diabetes and Metabolism (1.4k citations). Marion de Jong has collaborated with scholars based in Netherlands, Greece and Switzerland. Frequent co-authors include Eric P. Krenning, Dik J. Kwekkeboom, Willem H. Bakker, Roelf Valkema, P.P.M. Kooij, Wout A. P. Breeman, E. P. Krenning, Bert F. Bernard, Mark Konijnenberg and Marleen Melis. Their work appears in journals such as European Journal of Nuclear Medicine and Molecular Imaging, Journal of Nuclear Medicine, Nuclear Medicine and Biology, EJNMMI Research and Cancer Biotherapy and Radiopharmaceuticals.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact